176 related articles for article (PubMed ID: 23604466)
1. Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor.
Lee SH; Kim N; Kim SJ; Song J; Gong YD; Kim SY
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1279-94. PubMed ID: 23604466
[TBL] [Abstract][Full Text] [Related]
2. The mechanism of transglutaminase 2 inhibition with glucosamine: implications of a possible anti-inflammatory effect through transglutaminase inhibition.
Jeong KC; Ahn KO; Lee BI; Lee CH; Kim SY
J Cancer Res Clin Oncol; 2010 Jan; 136(1):143-50. PubMed ID: 19655169
[TBL] [Abstract][Full Text] [Related]
3. Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition.
Kim DS; Park KS; Jeong KC; Lee BI; Lee CH; Kim SY
Cancer Lett; 2009 Jan; 273(2):243-9. PubMed ID: 18804908
[TBL] [Abstract][Full Text] [Related]
4. Depletion of cathepsin D by transglutaminase 2 through protein cross-linking promotes cell survival.
Kim SJ; Kim KH; Ahn ER; Yoo BC; Kim SY
Amino Acids; 2013 Jan; 44(1):73-80. PubMed ID: 21960143
[TBL] [Abstract][Full Text] [Related]
5. GTP, an inhibitor of transglutaminases, is hydrolyzed by tissue-type transglutaminase (TGase 2) but not by epidermal-type transglutaminase (TGase 3).
Hitomi K; Ikura K; Maki M
Biosci Biotechnol Biochem; 2000 Mar; 64(3):657-9. PubMed ID: 10803976
[TBL] [Abstract][Full Text] [Related]
6. Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models.
Ku BM; Kim SJ; Kim N; Hong D; Choi YB; Lee SH; Gong YD; Kim SY
J Cancer Res Clin Oncol; 2014 May; 140(5):757-67. PubMed ID: 24610445
[TBL] [Abstract][Full Text] [Related]
7. Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation.
Kim DS; Park SS; Nam BH; Kim IH; Kim SY
Cancer Res; 2006 Nov; 66(22):10936-43. PubMed ID: 17108131
[TBL] [Abstract][Full Text] [Related]
8. Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia.
Lee J; Kim YS; Choi DH; Bang MS; Han TR; Joh TH; Kim SY
J Biol Chem; 2004 Dec; 279(51):53725-35. PubMed ID: 15471861
[TBL] [Abstract][Full Text] [Related]
9. Novel 3-arylethynyl-substituted thieno[3,4-b]pyrazine derivatives as human transglutaminase 2 inhibitors.
Kim N; Kwak SH; Lee SH; Juvekar V; Lee BI; Ahn HC; Kim SY; Gong YD
Org Biomol Chem; 2014 Jul; 12(27):4932-40. PubMed ID: 24879506
[TBL] [Abstract][Full Text] [Related]
10. Renal cell carcinoma escapes death by p53 depletion through transglutaminase 2-chaperoned autophagy.
Kang JH; Lee JS; Hong D; Lee SH; Kim N; Lee WK; Sung TW; Gong YD; Kim SY
Cell Death Dis; 2016 Mar; 7(3):e2163. PubMed ID: 27031960
[TBL] [Abstract][Full Text] [Related]
11. TNF-alpha mediated NF-kappaB activation is constantly extended by transglutaminase 2.
Park KS; Kim DS; Ko C; Lee SJ; Oh SH; Kim SY
Front Biosci (Elite Ed); 2011 Jan; 3(1):341-54. PubMed ID: 21196314
[TBL] [Abstract][Full Text] [Related]
12. Cinnamoyl inhibitors of tissue transglutaminase.
Pardin C; Pelletier JN; Lubell WD; Keillor JW
J Org Chem; 2008 Aug; 73(15):5766-75. PubMed ID: 18582115
[TBL] [Abstract][Full Text] [Related]
13. A fluorescence anisotropy-based assay for determining the activity of tissue transglutaminase.
Hauser C; Wodtke R; Löser R; Pietsch M
Amino Acids; 2017 Mar; 49(3):567-583. PubMed ID: 26886924
[TBL] [Abstract][Full Text] [Related]
14. Silencing of TGase 2 sensitizes breast cancer cells to apoptosis by regulation of survival factors.
Kim DS; Park KS; Kim SY
Front Biosci (Landmark Ed); 2009 Jan; 14(7):2514-21. PubMed ID: 19273216
[TBL] [Abstract][Full Text] [Related]
15. Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor.
Case A; Stein RL
Biochemistry; 2007 Jan; 46(4):1106-15. PubMed ID: 17240993
[TBL] [Abstract][Full Text] [Related]
16. Development of a mechanism-based assay for tissue transglutaminase--results of a high-throughput screen and discovery of inhibitors.
Case A; Ni J; Yeh LA; Stein RL
Anal Biochem; 2005 Mar; 338(2):237-44. PubMed ID: 15745743
[TBL] [Abstract][Full Text] [Related]
17. Anti-inflammatory effects of the R2 peptide, an inhibitor of transglutaminase 2, in a mouse model of allergic asthma, induced by ovalbumin.
Kim DY; Park BS; Hong GU; Lee BJ; Park JW; Kim SY; Ro JY
Br J Pharmacol; 2011 Jan; 162(1):210-25. PubMed ID: 20840469
[TBL] [Abstract][Full Text] [Related]
18. I-kappaBalpha depletion by transglutaminase 2 and mu-calpain occurs in parallel with the ubiquitin-proteasome pathway.
Kim DS; Han BG; Park KS; Lee BI; Kim SY; Bae CD
Biochem Biophys Res Commun; 2010 Aug; 399(2):300-6. PubMed ID: 20659425
[TBL] [Abstract][Full Text] [Related]
19. A new regulatory mechanism of NF-kappaB activation by I-kappaBbeta in cancer cells.
Kim JM; Voll RE; Ko C; Kim DS; Park KS; Kim SY
J Mol Biol; 2008 Dec; 384(4):756-65. PubMed ID: 18950638
[TBL] [Abstract][Full Text] [Related]
20. Transglutaminase-2 induces N-cadherin expression in TGF-β1-induced epithelial mesenchymal transition via c-Jun-N-terminal kinase activation by protein phosphatase 2A down-regulation.
Park MK; You HJ; Lee HJ; Kang JH; Oh SH; Kim SY; Lee CH
Eur J Cancer; 2013 May; 49(7):1692-705. PubMed ID: 23290789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
